OMERS ADMINISTRATION Corp Acquires Shares of 13,953 West Pharmaceutical Services, Inc. $WST

OMERS ADMINISTRATION Corp bought a new position in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 13,953 shares of the medical instruments supplier’s stock, valued at approximately $5,009,000.

A number of other institutional investors have also modified their holdings of WST. Elyxium Wealth LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $25,000. CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services during the 2nd quarter worth $25,000. Cornerstone Planning Group LLC raised its position in West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 50 shares in the last quarter. Bayban purchased a new stake in shares of West Pharmaceutical Services in the 4th quarter worth $27,000. Finally, Avalon Trust Co purchased a new position in shares of West Pharmaceutical Services during the second quarter valued at $28,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $353.33 on Tuesday. The business has a fifty day moving average of $349.06 and a 200 day moving average of $301.06. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market capitalization of $24.87 billion, a price-to-earnings ratio of 45.24, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same quarter in the prior year, the company earned $1.84 EPS. West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, research analysts expect that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.27%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Citigroup lifted their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Morgan Stanley upped their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.